Abstract
The very early intuition of Paget about the molecular feature of metastasis has come in the field of therapeutic opportunities only in the last few years with the development of targeted therapy. However, to date the diagnosis of metastases is associated in the majority of cases with the loss of any therapeutic hope. According to present knowledge, metastatic spreading is considered as part of a long process in which tumor cells gain new properties in their cellular function, including invasion and adaptive survival. This gain of function is based on the expression of new molecular markers that may be potential therapeutic targets in blocking tumor dissemination. The epidermal growth factor receptor family comprises four members (ERBB) that are frequently upregulated in advanced tumor stages and have been associated with the metastatic potential of several tumors. ERBB receptor inhibitors are very effective against specific primary tumors and their use is frequently accompanied by toxicity problems, drug resistance and molecular desensitization. However, new studies indicate that ERBB inhibitors may provide a much-needed therapeutic option mainly for patients with metastases. In order to illustrate the potential of ERBB family members as therapeutic targets in blocking metastases we summarize the new molecular evidence and the observations from clinical trials.
Keywords: Targeted therapy, epidermal growth factor, EGF, tumor invasion, tyrosine kinases, clinical trials
Current Cancer Drug Targets
Title: Targeting ERBB Receptors to Inhibit Metastasis: Old Hopes and New Certainties
Volume: 9 Issue: 1
Author(s): Adriano Angelucci
Affiliation:
Keywords: Targeted therapy, epidermal growth factor, EGF, tumor invasion, tyrosine kinases, clinical trials
Abstract: The very early intuition of Paget about the molecular feature of metastasis has come in the field of therapeutic opportunities only in the last few years with the development of targeted therapy. However, to date the diagnosis of metastases is associated in the majority of cases with the loss of any therapeutic hope. According to present knowledge, metastatic spreading is considered as part of a long process in which tumor cells gain new properties in their cellular function, including invasion and adaptive survival. This gain of function is based on the expression of new molecular markers that may be potential therapeutic targets in blocking tumor dissemination. The epidermal growth factor receptor family comprises four members (ERBB) that are frequently upregulated in advanced tumor stages and have been associated with the metastatic potential of several tumors. ERBB receptor inhibitors are very effective against specific primary tumors and their use is frequently accompanied by toxicity problems, drug resistance and molecular desensitization. However, new studies indicate that ERBB inhibitors may provide a much-needed therapeutic option mainly for patients with metastases. In order to illustrate the potential of ERBB family members as therapeutic targets in blocking metastases we summarize the new molecular evidence and the observations from clinical trials.
Export Options
About this article
Cite this article as:
Angelucci Adriano, Targeting ERBB Receptors to Inhibit Metastasis: Old Hopes and New Certainties, Current Cancer Drug Targets 2009; 9 (1) . https://dx.doi.org/10.2174/156800909787314048
DOI https://dx.doi.org/10.2174/156800909787314048 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet Our Editorial:
Anti-Cancer Agents in Medicinal Chemistry Anticancer Agents Based on Vulnerable Components in a Signalling Pathway
Mini-Reviews in Medicinal Chemistry Novel Targeted Therapies and Combinations for the Treatment of Multiple Myeloma
Cardiovascular & Hematological Disorders-Drug Targets Editorial (Thematic Issue: Molecular Aspects of Cancer Resistance to Biological and Non- Biological Drugs and Strategies to Overcome Resistance)
Current Medicinal Chemistry Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer
Current Cancer Drug Targets MicroRNAs in Cancer Stem Cells: New Regulators of Stemness
Current Pharmaceutical Design Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation
Current Cancer Drug Targets Immunopathology of Rheumatoid Arthritis
Current Topics in Medicinal Chemistry Elastic Bilayer Vesicles of Flurbiprofen for Transdermal Delivery: Development and In-Vitro Characterization
Drug Delivery Letters Low Dose Chest Computed Tomography, in Identifying Pulmonary Complications in Immunocompromised Patients After Allogeneic Hematopoietic Stem Cell Transplantation
Current Respiratory Medicine Reviews A Mechanistic Overview on Male Infertility and Germ Cell Cancers
Current Pharmaceutical Design Therapeutic Agents Based on DNA Sequence Specific Binding
Current Topics in Medicinal Chemistry Clinical Utility of Microarrays: Current Status, Existing Challenges and Future Outlook
Current Genomics Small Animal Computed Tomography Imaging
Current Medical Imaging Nanosponge: A Novel Carrier for Drug Delivery
Drug Delivery Letters Progress in Drug and Formulation Development for the Chemoprevention of Oral Squamous Cell Carcinoma: A Review
Recent Patents on Drug Delivery & Formulation Uncovering the Diversification of Tissue Engineering on the Emergent Areas of Stem Cells, Nanotechnology and Biomaterials
Current Stem Cell Research & Therapy Pre-viable Newborns in Saudi Arabia: Where are We Now and What the Future May Hold?
Current Pediatric Reviews Gene Delivery for Periodontal Tissue Engineering: Current Knowledge – Future Possibilities
Current Gene Therapy CARD Proteins as Therapeutic Targets in Cancer
Current Drug Targets